Oncotelic Therapeutics Inc. (OTCQB: OTLC) has unveiled a breakthrough nanomedicine platform called Deciparticle, which can reliably formulate diverse hydrophobic drugs—including macrolide mTOR inhibitors, peptides, and polyketides—into uniform, intravenous-ready nanoparticles. The company also announced the expansion of its Everolimus (Afinitor) pipeline with Sapu003, an intravenous formulation developed using the platform.
Preclinical pharmacokinetic data presented at the 2025 San Antonio Breast Cancer Symposium showed that Sapu003 reduces gastrointestinal drug accumulation by up to 67-fold compared to oral dosing of Everolimus. This reduction could potentially mitigate the gastrointestinal side effects commonly associated with oral mTOR inhibitors, a significant concern in cancer therapy.
The Deciparticle platform demonstrated high compatibility across therapeutic categories, successfully formulating all five main macrolide mTOR inhibitors—temsirolimus, sirolimus, ridaforolimus, Everolimus, and umirolimus—into stable, monodisperse particles. Additionally, tacrolimus, a key immunosuppressant, also formed stable nanoparticles. This modular, cGMP-ready nanomedicine engineering approach enables a quickly expanding immunology and oncology pipeline.
According to the company, the platform can package even the toughest water-resistant drugs into smaller, uniform nanoparticles suitable for safe intravenous use. More details on the platform and data can be found at ibn.fm/LxQ7N.
These advancements position Oncotelic as a key player in next-generation drug delivery, with scalable nanotechnology that could transform paradigms in immunology and oncology treatments. The company continues to leverage Sapu Nano, its clinical-stage nanomedicine, to drive innovation.
For ongoing updates, visit the company’s newsroom at ibn.fm/OTLC.
This news matters because it addresses a critical challenge in drug delivery: formulating hydrophobic drugs into effective intravenous therapies while reducing side effects. The platform's ability to handle multiple drug classes suggests broad applicability, potentially improving treatment options for cancer and immune-related diseases.
